Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA

NKTR-181 is a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in adult patients new to opioid therapy. NKTR-181 is a new molecular entity...This story is related to the following:Prescription Drugs
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news